EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-06

Study Completion Date

2025-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)

NCT03873714

Intracranial Aneurysm

TERMINATED NA

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

NCT06604884

Intracranial Aneurysm

RECRUITING

Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy

NCT02719522

Intracranial Aneurysm

COMPLETED

Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms

NCT03815149

Intracranial Aneurysm Cerebral Aneurysm Subarachnoid Hemorrhage +4 more

UNKNOWN

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)

NCT00402740

Carotid Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ELEVATE study is a prospective, multi-center, single-arm trial of the Pipeline™ Shield Device for the treatment of adults with acutely ruptured intracranial aneurysms. The primary objective of the ELEVATE study is to assess the safety and effectiveness of treatment with the Pipeline™ Shield Device of acutely ruptured intracranial aneurysms that are not amenable for clipping and coiling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracranial Aneurysm Ruptured Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pipeline™ Flex Embolization Device with Shield Technology™

This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.

Group Type EXPERIMENTAL

Pipeline™ Flex Embolization Device with Shield Technology™

Intervention Type DEVICE

The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pipeline™ Flex Embolization Device with Shield Technology™

The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pipeline™ Shield Device

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has a previously untreated, wide neck, side-wall, intradural aneurysm that is deemed unfavorable for both surgical clipping and endovascular coiling, as confirmed on DSA.
2. Subject has a ruptured intracranial aneurysm with vessel diameter suitable for treatment with the study device.
3. Subject is ≥ 22 and ≤ 80 years of age.
4. Subject has an acutely ruptured aneurysm with Hunt and Hess Scale 1, 2 or 3.
5. Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent.

Exclusion Criteria

1. Subject's vessel characteristics preclude safe endovascular access to the aneurysm to treat with the Pipeline™ Shield Device.
2. Subject has aneurysm vessel characteristics that would preclude the device from fully conforming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement.
3. Subject has true bifurcation or aneurysms with vessels that cannot be separated from the fundus with placement of the study device.
4. Subject with intraparenchymal hemorrhage.
5. Subject is unable to undergo nasogastric/orogastric tube placement prior to device placement.
6. Subject has a pre-morbid mRS \>2.
7. Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm.
8. Subject has a target ruptured aneurysm that is thought to be mycotic, including those caused by left atrial myxoma, or subject has an active systemic bacterial infection.
9. Subject with a requirement for continuous anti-coagulation.
10. Subject has a malignant brain tumor or vascular malformation (e.g. arteriovenous malformation).
11. Subject's target ruptured aneurysm has not been determined by the treating physician to be the source of SAH.
12. Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum).
13. Subject has a known hypersensitivity to ticagrelor or aspirin.
14. Subject is unable to undergo DSA or DSA is determined unsuitable by the treating physician.
15. Subject has a serious or life-threatening comorbidity that could confound study results.
16. Subject is at high risk of noncompliance per treating physician due to reasons including but not limited to a history of substance abuse.
17. Subject is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 24 months.
18. Subject is pregnant, or breastfeeding at the time of admission or plans to become pregnant during their participation in the study.
19. Subject is participating in another clinical study at the time of enrollment.
20. Presumed septic embolus, or suspicion of microbial superinfection.
21. Subject with a known COVID-19 viral infection, confirmed by testing.
22. Subject in whom a pre-existing stent is in place in the parent artery at target aneurysm location.

Minimum Eligible Age

22 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No